Evaluation the effect of raltegravir, and raltegravir/interferon beta combination on covid 19 patients

Phase 3

• Conditions: U07.1; COVID-19.; COVID-19 disease

• Registration Number: IRCT20200412047042N1
• Lead Sponsor: Jahrom University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 15 June 2020

Recruitment & Eligibility

• Status: Pending
• Sex: All
• Target Recruitment: 60

Inclusion Criteria

confirmed diagnosis of COVID19 with RT-PCR hospitalized patients

Exclusion Criteria

Patients with severe dyspnea require mechanical ventilation or hospitalization in intensive care units
and patients with treatment-resistant hypoxemia or those with severe underlying disease
Pregnancy or breastfeeding
Drug allergy
Patient dissatisfaction

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
In this study, Sequential Organ Failure Assessment (SOFA) will be used to assess the severity of the disease. In this criterion, respiratory systems (PaO2 / Fio2 measurement), coagulation (platelet count), liver (bilirubin level), cardiovascular (hypotension), central nervous system (CNS) and kidney (creatinine level or urinary tract) Will be reviewed. Each parameter is graded on a 5-point Likert scale (score between zero and 4). The total score is between zero and 28. Higher scores indicate a worse patient condition. Timepoint: Before and after the intervention. Method of measurement: The data will be collected using the information in the patient's file.